Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Uses of MRD in patients with multiple myeloma

Rafael Fonseca • 1 Jun 2018
ASCO 2018
Multiple Myeloma

In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be used in the treatment of multiple myeloma (MM), including how his practice uses MRD. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

More from Rafael Fonseca

0:57
Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Dec 2023
1:04
The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Jan 2024
2:10
DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca • 9 Dec 2023
1:52
Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca • 9 Dec 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals